Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3)

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Projects can enter either at the Discovery stage or at the Development stage.

Funding: No fixed limit 

Duration: UG3 1 year; UH3 4 years 

Research Authority due date: 10 days prior to submission

LOI (encouraged) due dates: 11.7.20, 9.1.21, 10.7.21, 9.1.22, 9.7.22, 9.1.23

Full proposal due dates:  11.8.20, 9.2.21, 10.8.21, 9.2.22, 9.8.22, 9.2.23